

CONTACT – Media:

Amsterdam +31.20.721.4488
Lisbon +351.210.600.614

Brussels +32.2.620.15.50
Paris +33.1.70.48.24.45

CONTACT – Investor Relations:

+33.1.70.48.24.17

THERANEXUS TAKES ITS FIRST STEPS ON EURONEXT GROWTH

€19.6 million successfully raised, for a total market capitalisation of approximately €47.5 million.



Paris – 30 October 2017 – Theranexus, a French biotech company that develops drugs for the treatment of central nervous system disorders, celebrated today its listing on Euronext Growth (ticker code: ALTHX). Theranexus was part of the first TechShare class of 2015, and is the third company in the programme to go public, joining a community of over 330 tech companies listed on Euronext.

Founded in 2013 by researchers at the CEA (French Alternative Energies and Atomic Energy Commission), Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders – including narcolepsy, Parkinson’s disease, Alzheimer’s disease and neuropathic pain. Theranexus has successfully identified the key role that non-neuronal cells (or “glial cells”) play in how neurons respond to CNS drugs. The company designs and develops ground-breaking drugs that act simultaneously on both cell types within the brain.

Theranexus’ unique patented technology is designed to increase the efficacy of previously approved and marketed CNS drugs by combining them with glial cell modulators. By combining and repurposing drugs in this way, the company can substantially cut development time and cost – thereby boosting its drug candidates’ chances of making it to the market. The proprietary, scalable Theranexus platform is able to generate a variety of high value-added proprietary drugs for several therapeutic indications. Theranexus is currently developing three candidate drugs for four indications. THN102, the most advanced one, is already in phase II clinical trials.

Theranexus was listed through the admission to trading on 30 October 2017. The company has a total of 3,065,390 shares, including 1,262,194 new shares issued as part of a Global Offering¹, raised €19.6 million after full exercise of the extension clause, which may rise to €21.0 million if the over-allotment option is fully exercised.

The Offering price was set at €15.50 per share. The company’s total market capitalisation the day of its IPO was €47.5 million.

¹The Global Offering is a public offering that consists of an open-price offering and a private placement among institutional investors in France and abroad.

Franck Mouthon, Theranexus Co-founder, Chairman and CEO, said: *“We would like to thank the institutional investors and individuals who believe in our company and took part in our IPO. And we would especially like to thank our long-standing shareholders who have renewed their support, giving us their full backing for our ambitious growth strategy. The funds we raised will let us continue to proactively develop and leverage our platform and portfolio of drug candidates.”*

TechShare is a pan-European programme launched by Euronext in 2015 to help leaders of tech SMEs to better understand financial markets and how they work. Spanning individual coaching sessions, talks and workshops, the ten-month course enabled Theranexus to weigh the benefits of going public as a way to finance its growth strategy.



Note to all news desks –

For more information on TechShare, visit TheTechCorner, Euronext’s website dedicated to Tech financing through capital markets:

<https://tech.euronext.com/fr/enternext-services/techshare>

CONTACT –

ACTUS finance & communications

Investor Relations

Théo Martin
+33 (0)1 53 67 36 75
tmartin@actus.fr

Caroline Lesage
+33 (0)1 53 67 36 79
clesage@actus.fr

Business and Financial Media Relations

Alexandra Prisa
+33 (0)1 53 67 36 90
aprisa@actus.fr

FP2COM

Florence Portejoie
+33 (0)6 07 76 82 83
fportejoie@fp2com.fr

Euronext:

Pauline Bucaille (Europe): +33 1 70 48 24 41; pbucaille@euronext.com
Aichata Tandjigora (Paris): +33 1 70 48 24 43; atandjigora@euronext.com

About Theranexus

Founded in 2013, Theranexus is a biopharmaceutical company founded by researchers at the CEA (French Alternative Energies and Atomic Energy Commission) that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus has successfully identified the key role that non-neuronal cells (or “glial cells”) play in how neurons respond to CNS drugs. The company designs and develops ground-breaking drugs that act simultaneously on both cell types within the brain. Theranexus’ unique patented technology is designed to increase the efficacy of previously approved and marketed CNS drugs by combining them with glial cell modulators. By combining and repurposing drugs in this way, the company can substantially cut development time and cost – thereby boosting its drugs’ chances of making it to the market.

The proprietary, scalable Theranexus platform is able to generate a variety of high value-added proprietary drugs for several therapeutic indications.

Theranexus has financial backing from CEA Investissement, Auriga Partners, Sofimac Partners and Kreaxi.

For more information, visit www.theranexus-bourse.com

About Euronext

Euronext is the leading pan-European exchange in the Eurozone with nearly 1,300 listed issuers worth close to €3.6 trillion in market capitalisation as of end September 2017, an unmatched blue chip franchise consisting of 24 issuers in the Morningstar® Eurozone 50 IndexSM and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM (formerly known as Alternext) and Euronext AccessTM (formerly known as the Free Market).

For the latest news, find us on Twitter (<https://twitter.com/euronext>) and LinkedIn (<https://www.linkedin.com/company/euronext>).

Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2017, Euronext N.V. – All rights reserved.